← All trials
NCT06816433
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Mar 31, 2026
- Completion date
- Sep 30, 2026
- First posted
- Feb 10, 2025
- Last posted
- Sep 8, 2025
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Global Coalition for Adaptive ResearchLead sponsor
- CitelineCollaborator
- Berry ConsultantsCollaborator
- United States ArmyCollaborator
- Cambridge Cognition LtdCollaborator
- PPDCollaborator
- Idorsia Pharmaceuticals Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.